Navigation Links
ADVENTRX Announces Consolidation of Clinical and Management Positions
Date:1/30/2008

Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical or clinical data suggests or as otherwise anticipated; the results of pending clinical trials for ADVENTRX's product candidates; the FDA's views on the appropriateness of seeking marketing approval of certain of ADVENTRX's product candidates under Section 505(b)(2); difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ADVENTRX's product candidates, including receiving necessary regulatory approvals for clinical trials of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non-patent exclusivity covering ADVENTRX's Section 505(b)(2) product candidates; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place u
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... July 30, 2014 Sales Horizons, a ... of blended sales training programs for companies engaged in ... programs used by thousands of salespeople over 25 years ... training program can be customized to address the unique ... blended sales training program consists of two ...
(Date:7/30/2014)... July 30, 2014 Vycom announces the ... products, designed to meet Factory Mutual (FM) 4910 fire ... such as wet benches, process tools, fume hoods, furniture ... and damage to semiconductor wafers used in electronic chip ... flame-retardant PVC solution with excellent workability and superior aesthetics. ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities for ... world,s leading pharmaceutical companies, today announced the signing of ... both new business contracts and repeat business to be ...
... ETEX Corporation, a leading orthopaedic biomaterials company, ... 2.5cc sizes of Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) ... 10cc sizes. Both products are bone substitute materials ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ...
... Hospira, Inc. (NYSE: HSP ), a ... today that Brian Meadows has been named corporate ... will be responsible for enterprise-wide supply chain operations ... supplier management; procurement; materials and production planning; transportation ...
Cached Biology Technology:Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty 2Hospira Names Brian Meadows Supply Chain Chief 2
(Date:7/30/2014)... (OUP) is pleased to announce its new relationship with ... OUP and CINP will partner to publish International ... fully open-access journal. , Alan Frazer, Editor-in-Chief of ... and expertise of OUP will further facilitate the goal ... the very leading journals within neuropsychopharmacology. The conversion of ...
(Date:7/30/2014)... $1 million from the Cornelia Cogswell Rossi Foundation to ... , The newly established Connie Cogswell Rossi ... a greater breadth and depth of knowledge of neurobehavioral ... of research to improve human health. , The new ... Laboratory and its external partners, supporting research to enhance ...
(Date:7/30/2014)... Soon, protection from HIV infection could be as simple ... sex. , University of Washington bioengineers have discovered ... that protects women from contracting HIV. Their method spins ... in contact with moisture, releasing higher doses of the ... gels or creams. , "This could offer women a ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... chocolate or the bitter taste of strychnine would seem to ... be hard-wired into the brain. Indeed, in studies with the ... in the January 19, 2006, issue of Neuron experiments demonstrating ... favor a model for taste encoding in the brain that ...
... announced today a critical step on the path of realizing ... described in the April 21 issue of Cell, the researchers ... ES cells that help explain the cells' rare ability to ... appear near the master genes that control embryonic development and ...
... equal. They are separated into categories A through C, ... easy to spread, kill effectively and call for special ... worrisome organisms is anthrax, which has already received its ... Fischetti's laboratory at Rockefeller University suggests that a newly ...
Cached Biology News:How taste response is hard-wired into the brain 2Novel molecular 'signature' marks DNA of embryonic stem cells 2Novel molecular 'signature' marks DNA of embryonic stem cells 3Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... has recently launched a custom synthesis ... (siRNA). Thermos siRNA molecules are: ... 2 DNA bases overhang at the ... Delivered fully deprotected and ready-to-use. ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
Biology Products: